3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
fludarabine
3
Vaccines
3
Radiotherapy
3
Papillomavirus Vaccines
3
Nivolumab
3
Cyclophosphamide
3
pembrolizumab
2
entinostat
2
aldesleukin
2
aflibercept
2
Trastuzumab
2
Surveys and Questionnaires
2
Specimen Handling
2
Radiation
2
Observation
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tivozanib
1
tipifarnib
1
rocakinogene sifuplasmid
1
oncogene protein E7, Human papillomavirus type 16
1
nanocis
1
durvalumab
1
bintrafusp alfa protein, human
1
atezolizumab
1
Watchful Waiting
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
nanocis
×
Gastrointestinal
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled